We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
When 90% Isn't an A+: Elevance's Cost Crunch and Carelon's Cushion
Read MoreHide Full Article
Key Takeaways
Elevance sees a 2025 benefit expense ratio near 90%, up from 88.5% in 2024.
Commercial individual membership rose 9.7% in 1H 2025.
Carelon revenues are expected to climb nearly 30% in 2025, led by Carelon Services' 60% surge.
Elevance Health, Inc. (ELV - Free Report) , like most peers in the health benefits space, is contending with pressure from rising medical cost trends in ACA plans, slower Medicaid rate recovery, and higher utilization, prompting a reduction in its 2025 outlook. In the first half of the year, benefits expense surged nearly 18% to more than $72 billion, while cost of products sold climbed almost 19% to $10.3 billion.
The second-quarter benefit expense ratio reached 88.9%, up 260 basis points year over year. Elevance now projects a full-year ratio of about 90%, versus 88.5% in 2024. This leaves a smaller share of premiums after paying claims, compressing margins. However, growth in the commercial segment and Carelon operations should offer support.
Commercial individual memberships rose 9.7% in the first half of 2025, following a 25.6% increase in 2024. The broader commercial business, typically enjoying higher margins, is expected to sustain its expansion. Carelon’s expanding value-based care model and pharmacy services will also provide a stabilizing influence.
In the CarelonRx unit, growing adjusted scripts and acquisitions should drive performance, while operational gains in Carelon Health will aid the Carelon Services arm. Diversification efforts have boosted Carelon’s overall revenue contribution, with segment growth of 12.4% in 2024 and a 36.8% jump in the first half of 2025. For full-year 2025, we expect it to advance nearly 30%, fueled by about 60% growth in Carelon Services alone.
Together, Elevance’s commercial strength and Carelon’s diversified growth could help counterbalance margin pressures from elevated medical costs and funding challenges in government programs.
How ELV’s Peers Are Suffering?
Companies like UnitedHealth Group Incorporated (UNH - Free Report) and Centene Corporation (CNC - Free Report) are also facing the brunt of rising medical costs.
UNH’s medical care ratio was 89.4% in the second quarter, which deteriorated 430 bps from the year-ago period. UnitedHealth reported Q2 adjusted EPS of $4.08, which missed the Zacks Consensus Estimate of $4.84. Meanwhile, Centene’s health benefits ratio of 93% deteriorated 540 basis points year over year in the second quarter and came above the consensus mark of 90.82%. Centene reported adjusted loss per share of 16 cents in the second quarter, which missed the Zacks Consensus Estimate of earnings of 68 cents.
Elevance’s Price Performance, Valuation and Estimates
Shares of ELV have lost 20.7% in the year-to-date period compared with the industry’s decline of 3.9%.
Image Source: Zacks Investment Research
From a valuation standpoint, Elevance trades at a forward price-to-earnings ratio of 9.19, down from the industry average of 14.57. ELV has a Value Score of A at present.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Elevance’s 2025 earnings is pegged at $30.59 per share, implying a 7.4% decline from the year-ago period.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #5 (Strong Sell).
Image: Bigstock
When 90% Isn't an A+: Elevance's Cost Crunch and Carelon's Cushion
Key Takeaways
Elevance Health, Inc. (ELV - Free Report) , like most peers in the health benefits space, is contending with pressure from rising medical cost trends in ACA plans, slower Medicaid rate recovery, and higher utilization, prompting a reduction in its 2025 outlook. In the first half of the year, benefits expense surged nearly 18% to more than $72 billion, while cost of products sold climbed almost 19% to $10.3 billion.
The second-quarter benefit expense ratio reached 88.9%, up 260 basis points year over year. Elevance now projects a full-year ratio of about 90%, versus 88.5% in 2024. This leaves a smaller share of premiums after paying claims, compressing margins. However, growth in the commercial segment and Carelon operations should offer support.
Commercial individual memberships rose 9.7% in the first half of 2025, following a 25.6% increase in 2024. The broader commercial business, typically enjoying higher margins, is expected to sustain its expansion. Carelon’s expanding value-based care model and pharmacy services will also provide a stabilizing influence.
In the CarelonRx unit, growing adjusted scripts and acquisitions should drive performance, while operational gains in Carelon Health will aid the Carelon Services arm. Diversification efforts have boosted Carelon’s overall revenue contribution, with segment growth of 12.4% in 2024 and a 36.8% jump in the first half of 2025. For full-year 2025, we expect it to advance nearly 30%, fueled by about 60% growth in Carelon Services alone.
Together, Elevance’s commercial strength and Carelon’s diversified growth could help counterbalance margin pressures from elevated medical costs and funding challenges in government programs.
How ELV’s Peers Are Suffering?
Companies like UnitedHealth Group Incorporated (UNH - Free Report) and Centene Corporation (CNC - Free Report) are also facing the brunt of rising medical costs.
UNH’s medical care ratio was 89.4% in the second quarter, which deteriorated 430 bps from the year-ago period. UnitedHealth reported Q2 adjusted EPS of $4.08, which missed the Zacks Consensus Estimate of $4.84. Meanwhile, Centene’s health benefits ratio of 93% deteriorated 540 basis points year over year in the second quarter and came above the consensus mark of 90.82%. Centene reported adjusted loss per share of 16 cents in the second quarter, which missed the Zacks Consensus Estimate of earnings of 68 cents.
Elevance’s Price Performance, Valuation and Estimates
Shares of ELV have lost 20.7% in the year-to-date period compared with the industry’s decline of 3.9%.
From a valuation standpoint, Elevance trades at a forward price-to-earnings ratio of 9.19, down from the industry average of 14.57. ELV has a Value Score of A at present.
The Zacks Consensus Estimate for Elevance’s 2025 earnings is pegged at $30.59 per share, implying a 7.4% decline from the year-ago period.
The stock currently carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.